Mobia Medical, Inc.’s Board of Directors appointed Myriam J. Curet, M.D., to its nominating and corporate governance committee on October 15, 2026, effective immediately. The amendment supplements Mobia’s August 3, 2026 report solely to disclose the appointment; all other disclosures in that report remain unchanged.
Mobia Medical, Inc. amended its earlier current report solely to add a committee appointment. On October 15, 2026, its board appointed Reza Zadno, Ph.D., to serve on the audit committee, effective immediately. He will continue serving on the compensation committee. The amendment states that all other disclosures in the July 15, 2026 report remain unchanged.
Mobia Medical, Inc. (MOBI) insider Chase C. Leavitt, the company’s General Counsel and Corporate Secretary, purchased 2,000 shares of common stock on September 11, 2026 in a purchase described as an open market or private transaction at $10.30 per share. Following this transaction, Leavitt directly holds 5,000 Mobia Medical common shares. No Rule 10b5-1 trading plan is reported for this transaction.
Mobia Medical, Inc. (MOBI) reported that Chief Operating Officer Prashant B. Rawat exercised stock options for 15,000 shares of common stock on September 2, 2026 at an exercise price of $3.38 per share. The exercised options were fully vested and exercisable and were converted into an equal number of common shares.
Following the transactions, Rawat holds 30,000 shares of Mobia Medical common stock directly and retains 167,243 stock options directly. No Rule 10b5-1 trading plan is reported for these transactions.
Mobia Medical, Inc. (MOBI) director Casey M. Tansey reported an open-market purchase of 16,441 shares of common stock on August 18, 2026 at a weighted average price of $12.0749 per share. Following this transaction, Tansey directly holds 318,332 shares of Mobia Medical common stock. The purchase price reflects multiple trades executed between $11.90 and $12.70 per share.
Mobia Medical, Inc. director Casey M Tansey reported open-market purchases of 68,559 shares of common stock over three days in August 2026. Transactions included 35,572 shares on August 13 at a weighted average price of $11.5073, 15,821 shares on August 14 at weighted average and fixed prices, and 17,166 shares on August 17 at a weighted average price of $11.8509. Footnotes state that several reported prices are weighted averages based on multiple trades within disclosed price ranges. The Rule 10b5-1 checkbox was not marked as an affirmatively adopted trading plan.
Mobia Medical, Inc. received a beneficial ownership report from Green Park & Golf Ventures II, LLC and a group of affiliated investment entities and individuals. The Reporting Persons disclose 3,684,409 shares of Mobia Medical common stock, which they state represents 11.1% of the class.
The stake is held across numerous Delaware and Texas limited liability companies, including Green Park & Golf Ventures II, Green Park & Golf Ventures – Houston, and multiple GPG- and MTI-branded vehicles. Clay M. Heighten, MD, Carl D. Soderstrom and Gilbert G. Garcia II are managers of the managing entities and share voting and dispositive power, and may be deemed to beneficially own the securities held by these entities.
The ownership percentages are based on 33,291,096 shares outstanding as of August 6, 2026, as reported by Mobia Medical in a prior Form 10-Q. All reported powers over the shares are described as shared rather than sole.
Mobia Medical, Inc. has a significant ownership position reported by U.S. Venture Partners–affiliated entities and an individual director under a Schedule 13G. U.S. Venture Partners XII, L.P. reports beneficial ownership of 1,906,809 shares of common stock, representing 5.7% of the outstanding shares, with shared voting and dispositive power over all of these shares.
Presidio Management Group XII, L.L.C. reports beneficial ownership of 3,626,826 shares, or 10.9% of Mobia Medical’s common stock, all with shared voting and dispositive power. Casey M. Tansey, a U.S. citizen and a member of the issuer’s board, reports beneficial ownership of 3,860,158 shares, or 11.6%, including 233,332 shares over which he has sole voting and dispositive power and the remainder with shared power through venture funds.
All percentages are based on 33,249,006 shares of common stock outstanding as of June 1, 2026. The reporting persons state that they are not acting as a group and each disclaims beneficial ownership beyond any pecuniary interest.
Mobia Medical, Inc. reports strong top-line growth but continued losses for the six months ended June 30, 2026. Revenue was $25.6 million, up from $12.3 million, with a high gross margin of about 83%. Operating expenses increased sharply, led by selling, general and administrative costs, resulting in a net loss of $38.8 million versus $21.1 million a year earlier.
In May 2026 the company completed an IPO, selling 10,000,000 shares at $15.00 per share for net proceeds of about $134.0 million. All 65.6 million preferred shares and $40.0 million of convertible notes converted into common stock, moving from a stockholders’ deficit to $172.6 million of equity. Cash and cash equivalents rose to $177.1 million, and management now concludes existing liquidity is sufficient for at least one year, so prior substantial-doubt going-concern language no longer applies.
Mobia Medical, Inc. reported second quarter 2026 results with revenue of $13.5 million, an increase of 102% from $6.7 million a year earlier, driven by higher adoption of the Vivistim System and more IPG units sold. Gross profit was $11.2 million, and gross margin was 83.2% compared with 82.3% in the prior-year quarter.
Operating expenses rose to $29.2 million, up 83% from $16.0 million, reflecting expanded commercial personnel, commissions, development, and administrative costs. Net loss was $21.0 million, or $1.10 per share, versus a net loss of $10.5 million, or $12.44 per share, mainly due to higher expenses and a change in fair value of convertible notes.
As of June 30, 2026, cash and cash equivalents totaled $177.1 million, including approximately $134.0 million in net proceeds from an initial public offering completed in May 2026. For full year 2026, the company expects revenue of $54.0 million to $56.0 million, representing growth of 69% to 75% over 2025.